Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors

BACKGROUNDS/AIMS: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials. In this second stage of our ongoing study, we intend to analyze the...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Hepatobiliary Pancreat Surg
Main Authors: Thorat, Ashok, Jeng, Long-Bin, Yang, Horng-Ren, Yeh, Chun-Chieh, Hsu, Shih-Chao, Chen, Te-Hung, Poon, Kin-Shing
Formato: Artigo
Idioma:Inglês
Publicado: Korean Association of Hepato-Biliary-Pancreatic Surgery 2017
Assuntos:
Original Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5736740/
https://ncbi.nlm.nih.gov/pubmed/29264583
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14701/ahbps.2017.21.4.205
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares